We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
-19.25%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$585M
AUM Growth
-$382M
Cap. Flow
-$229M
Cap. Flow %
-39.19%
Top 10 Hldgs %
61.33%
Holding
429
New
88
Increased
84
Reduced
102
Closed
122

Top Buys

Rank Stock Value
1
ET icon
Energy Transfer Partners
ET
+$50.2M
2
EPD icon
Enterprise Products Partners
EPD
+$8.56M
3
OKE icon
Oneok
OKE
+$8.36M
4
AM
ANTERO MIDSTREAM PARTNERS LP
AM
+$3.06M
5
PSXP
PHILLIPS 66 PARTNERS LP
PSXP
+$2.72M

Top Sells

Rank Stock Value
1
ETP
Energy Transfer Partners, L.P.
ETP
+$77.3M
2
MPC icon
Marathon Petroleum
MPC
+$28.8M
3
EEP
Enbridge Energy Partners
EEP
+$23.6M
4
PSX icon
Phillips 66
PSX
+$16.9M
5
WMB icon
Williams Companies
WMB
+$16.7M

Sector Composition

Rank Sector Weight
1 Energy 82.73%
2 Healthcare 7.29%
3 Utilities 2.06%
4 Financials 0.12%
5 Technology 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
51
Vertex Pharmaceuticals
VRTX
$121B
$586K 0.1%
3,535
-1,516
-30% -$263K
HALO icon
52
Halozyme
HALO
$9.72B
$584K 0.1%
39,935
-1,264
-3% -$20.2K
ACOR
53
DELISTED
Acorda Therapeutics
ACOR
$578K 0.1%
309
+102
+49% +$222K
ENTA icon
54
Enanta Pharmaceuticals
ENTA
$372M
$577K 0.1%
8,140
+1,088
+15% +$83.4K
INCY icon
55
Incyte
INCY
$23.5B
$577K 0.1%
9,073
+8,331
+1,123% +$541K
BIIB icon
56
Biogen
BIIB
$29.9B
$574K 0.1%
1,909
-652
-25% -$208K
TBPH icon
57
Theravance Biopharma
TBPH
$874M
$574K 0.1%
22,443
-9,783
-30% -$264K
ALNY icon
58
Alnylam Pharmaceuticals
ALNY
$36.3B
$573K 0.1%
7,863
+3,436
+78% +$264K
RARE icon
59
Ultragenyx Pharmaceutical
RARE
$2.65B
$572K 0.1%
13,150
+3,709
+39% +$203K
EXEL icon
60
Exelixis
EXEL
$13.9B
$567K 0.1%
28,817
-11,034
-28% -$197K
XIFR
61
XPLR Infrastructure LP
XIFR
$1.18B
$566K 0.1%
13,149
– –
CELG
62
DELISTED
Celgene Corp
CELG
$566K 0.1%
8,835
-997
-10% -$73.6K
SGEN
63
DELISTED
Seagen Inc. Common Stock
SGEN
$565K 0.1%
9,963
-1,990
-17% -$125K
TVTX icon
64
Travere Therapeutics
TVTX
$5.33B
$561K 0.1%
24,796
-3,271
-12% -$81.4K
ICPT
65
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$560K 0.1%
5,560
-4,058
-42% -$421K
CLVS
66
DELISTED
Clovis Oncology, Inc.
CLVS
$555K 0.09%
30,876
+13,775
+81% +$281K
FOLD
67
DELISTED
Amicus Therapeutics
FOLD
$550K 0.09%
57,427
+28,582
+99% +$314K
BMRN icon
68
BioMarin Pharmaceuticals
BMRN
$11.5B
$549K 0.09%
6,453
-2,247
-26% -$214K
ARRY
69
DELISTED
Array Biopharma Inc
ARRY
$548K 0.09%
38,479
+12,195
+46% +$185K
IRWD icon
70
Ironwood Pharmaceuticals
IRWD
$611M
$547K 0.09%
63,069
+12,766
+25% +$147K
LXRX icon
71
Lexicon Pharmaceuticals
LXRX
$1.02B
$546K 0.09%
82,295
+21,567
+36% +$175K
NKTR icon
72
Nektar Therapeutics
NKTR
$2.39B
$545K 0.09%
1,106
+181
+20% +$109K
SRPT icon
73
Sarepta Therapeutics
SRPT
$1.66B
$543K 0.09%
4,976
-2,949
-37% -$369K
PBYI icon
74
Puma Biotechnology
PBYI
$406M
$534K 0.09%
26,259
+12,032
+85% +$361K
AGIO icon
75
Agios Pharmaceuticals
AGIO
$2.16B
$532K 0.09%
11,531
+3,316
+40% +$205K
1 2
3
4 5

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q4 2018 Portfolio in Review

As of Q4 2018, Virtus ETF Advisers held 429 positions worth $585M, down 40% from $968M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Virtus ETF Advisers withdrew a net $229M in Q4 2018, closing 122 positions and reducing 102 holdings. Its most notable exit was Energy Transfer Partners, L.P., an estimated $77.3M position sold in full.

By sector, the portfolio is most concentrated in Energy at 83% of assets, up from 68% a quarter earlier, followed by Healthcare and Utilities.

Against the trend, Virtus ETF Advisers opened a new position in Amyris Inc. worth $251K.

  • Virtus ETF Advisers's largest Q4 2018 buy was Amyris Inc.: 75,294 shares worth $251K.
  • Virtus ETF Advisers added most to Energy Transfer Partners in Q4 2018, an estimated $50.2M increase.
  • Virtus ETF Advisers's biggest Q4 2018 reduction was Marathon Petroleum, cutting an estimated $28.8M.
  • Virtus ETF Advisers fully exited Energy Transfer Partners, L.P. in Q4 2018, selling an estimated $77.3M.
  • Virtus ETF Advisers's ten largest holdings make up 61% of its $585M portfolio in Q4 2018.
  • Virtus ETF Advisers opened 88 new positions and closed 122 in Q4 2018.
  • Virtus ETF Advisers's portfolio value fell 40% quarter-over-quarter to $585M.

Based on Virtus ETF Advisers's 13F filing for Q4 2018, filed 5 Feb 2019.